中国经济网北京8月15日讯昨日，上海光大证券资产管理有限公司发布关于上海光大证券资产管理有限 公司旗下产品估值调整的公告。 根据《中国证券监督管理委员会关于证券投资基金估值业务的指导意见》(证监会公告[2017]13号)的要 求，经与托管人协商一致，自2025年8月13日起，上海光大证券资产管理有限公司(以下简称"本公司") 对旗下资产管理计划持有的"诺辉健康(证券代码：6606.HK)"按照0.01港元/股进行估值。 ...

Group 1 - The Hang Seng Biotechnology ETF (159615) has seen a 2.27% increase, marking a three-day rising streak with an active trading volume of 35.71% and a transaction value of 131 million yuan [1] - The Hang Seng Biotechnology Index, which the ETF tracks, rose by 1.67%, with notable increases in constituent stocks such as JD Health (up 12.22%) and Sihuan Pharmaceutical (up 8.49%) [1] - The ETF has accumulated a 2.72% increase over the past week, ranking first among comparable funds, and its latest scale reached 352 million yuan, a three-month high [1] Group 2 - According to Guojin Securities, China's innovative drugs are on the rise, entering the initial phase of innovation results realization, with significant opportunities for independent development and large-scale transactions in the future [2] - In the oncology field, two main directions are highlighted: the multidimensional iteration of ADCs (antibody-drug conjugates) and innovations in the combination of immune therapy molecular components [2] - The Hang Seng Biotechnology Index reflects the overall performance of the largest 50 biotechnology companies listed in Hong Kong, with top-weighted stocks including BeiGene, Innovent Biologics, and WuXi Biologics [2]

科技日报讯 （记者陈曦 通讯员赵晖）记者8月13日从天津大学获悉，该校王汉杰、刘夺团队与西北 农林科技大学杜涛峰团队合作，成功构建"可吞服光电子胶囊—工程菌双向交流系统"，为肠道健康监测 与疾病治疗开辟了新路径。相关研究成果发表在国际期刊《自然·微生物学》上。 据介绍，肠道内栖息着数以亿计的微生物，其组成和活动与人体健康密切相关。但由于肠道环境复 杂，传统检测和调控手段难以精准捕捉菌群的实时状态。此次研究团队研发的可吞服光电子胶囊，如 同"智能潜水艇"深入肠道，可通过光学信号实现与工程菌的双向交流。 该成果为肠道微生物研究提供了全新工具，未来结合人工智能和云技术，有望实现对肠道健康的动 态监测与精准调控，为肠炎等疾病的治疗开辟新途径。 在猪肠炎模型实验中，该系统能比传统检测方法提前1—2天捕捉到肠炎信号，且通过远程调控工程 菌可有效缓解炎症。这项技术构建了新型"菌—机接口"，为实现"人—机—菌交互"、推动智能化疾病诊 疗奠定了基础。 处于炎症状态的肠道细胞会产生异常高浓度的一氧化氮，并在肠道中很快转化为硝酸根，因此硝酸 根可以作为一种肠炎标志物。研究团队改造工程菌使其一旦"感受"到硝酸根便会发光，胶囊的光电传 ...

Group 1 - Core viewpoint: As of August 14, 2025, 12 institutional investors disclosed holdings in Nuohe Zhiyuan (688315.SH), totaling 88.87 million shares, which represents 21.35% of the company's total share capital [1] - The top ten institutional investors collectively hold 21.34% of the shares, with a 0.31 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, five new public funds were disclosed this period, including Hongde Advantage Leading Mixed, Qianhai Kaiyuan Event-Driven Mixed A, and Nord Quantitative Pioneer A [2] - Three public funds were not disclosed this period compared to the previous quarter, including Great Wall CSI 500 Index Enhanced A and Xingye CSI 500 Index Enhanced A [2]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $6.7 million, a decrease of 13% compared to Q2 2024, but a 5% decrease when adjusted for discontinued services [11] - Non-GAAP gross margin for Q2 2025 was 52%, significantly higher than the 35% reported a year ago [12] - Non-GAAP operating expenses for Q2 2025 were $8.8 million, down 53% from $18.8 million in Q2 2024 [12][16] - Cash and cash equivalents at the end of the quarter were $27.4 million, with $11 million subject to restrictions [13] Business Line Data and Key Metrics Changes - The company sold 7,233 flow cells in Q2 2025, reflecting a 17% increase year-over-year [12] - Revenue from consumables and software combined grew 16% year-over-year in Q2 2025 [15] - The percentage of consumables and software revenue increased from 55% in 2024 to 73% in Q2 2025 [15] Market Data and Key Metrics Changes - The optical genome mapping (OGM) community surpassed 10,000 published clinical research genomes, marking a significant milestone [19] - The 2025 quarter had the highest number of publications in the history of optical genome mapping [19] Company Strategy and Development Direction - The company is focusing on digital pathology, particularly in cytogenetics and molecular pathology, with plans to expand into clinical and anatomic pathology [6] - The strategy includes supporting routine users, driving utilization of VIA software, building reimbursement support for OGM, and improving profitability [10] - The company aims to consolidate workflows in pathology through AI-driven software and optical genome mapping [7][8] Management's Comments on Operating Environment and Future Outlook - Management reiterated full-year revenue guidance of $26 to $30 million, with Q3 revenues expected to be in the range of $6.7 to $7.2 million [20] - The company raised expectations for new OGM installations in 2025 to 20-25 systems, up from the previous range of 15-20 [20] - Management expressed confidence in the ongoing strategy and the potential for significant business upside [51] Other Important Information - The company has made substantial progress in reducing operating expenses, cutting over $100 million in annual non-GAAP operating expenses since 2023 [16] - The release of new software updates is expected to enhance the usability of OGM workflows [18] Q&A Session Summary Question: How universal is the use of VIA software among OGM users? - Management indicated that VIA is installed in about a third of the OGM systems, with higher adoption among routine users, suggesting significant opportunities for expansion [24][25] Question: Are there efforts to market VIA to non-OGM users? - Management confirmed that a substantial amount of software is sold for non-OGM applications, and there is potential for cross-selling to convert these users into OGM customers [27][28] Question: What role does AI play in the VIA software? - AI enhances the analysis of variants by leveraging databases to improve accuracy and speed in reporting [29] Question: Can you clarify the return rate for new systems placed? - Management stated it is premature to discuss return rates, but they expect low returns due to the strategic shift in customer focus [36][37] Question: How does the new CPT code differ from the first one? - The new CPT code is for constitutional genetic disorders, which may lead to differences in pricing and facilitate reimbursement [40][41] Question: Is the instrument placement guidance conservative? - Management acknowledged that the guidance is conservative, considering potential delays in installations [45] Question: What is the expected time for new customers to reach maturity? - It typically takes a minimum of three months, with six to nine months being a healthy timeframe for labs to reach routine use [47][48]

Core Viewpoint - The collaboration between Shanghai Zhiyu Biotechnology, Nanjing Normal University, and Changzhou Beiliguan Biotechnology aims to innovate and industrialize the production of taurine using a biocatalytic method, contributing to a green industry chain driven by synthetic biology [2][3][5]. Group 1: Collaboration Details - The partnership involves three parties: Zhiyu Biotechnology will focus on the core process development for biocatalytic taurine production, ensuring technological leadership and innovation [5]. - Nanjing Normal University will handle pilot-scale testing and technical validation to ensure stable experimental conditions and reliable results [5]. - Changzhou Beiliguan will provide market insights, focusing on market research, channel development, and promotion to facilitate the commercialization of the technological outcomes [5]. Group 2: Taurine Overview - Taurine is a significant ingredient in functional beverages and health products, with its green and efficient production technology being a focal point of industry interest [6]. - As a β-amino acid and a derivative of cysteine, taurine is abundant in various tissues in the human body and is widely used in pharmaceuticals and food sectors for its nutritional enhancement, immune support, and fatigue relief properties [6]. - The biosynthesis of taurine primarily occurs through a series of enzymatic reactions involving cysteine, leading to its final form, which is crucial for various physiological functions [6].

Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

Group 1 - The investment bank maintains a cautiously optimistic view on the Chinese pharmaceutical industry, noting a 137% average increase in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals [1] - Recent pullbacks in the industry are attributed to disappointing sales figures from major biotech companies and concerns over potential phased drug tariffs proposed by Trump, which could reach 150% within a year and ultimately 250% [1] - The bank's preferred focus is on innovative sectors with strong performance in the first half of 2025, highlighting BeiGene (06160) with a target price of HKD 230 and a rating of "outperform" due to its strong half-year results and improved gross margin guidance [1] Group 2 - The bank expects CanSino Biologics (09926) to report adjusted earnings of RMB 23 million in the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, with a rating of "outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "outperform," reflecting confidence in the company's projected 37% year-on-year growth in product revenue [1] - The bank continues to focus on licensing deals for innovative drugs in China, anticipating more subsidies for high-priced innovative drugs, which may drive sales growth for companies like Kintor Pharmaceutical (02171), Fosun Pharma (600196) (02196), WuXi AppTec (02126), and Kerenor Biotech (06990) [2]

Core Viewpoint - The investment bank maintains a cautiously optimistic outlook on the Chinese pharmaceutical industry, noting a significant average increase of 137% in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals and unaffected by upcoming U.S. tariffs [1] Group 1: Market Performance - The biotech sector has recently experienced some pullback due to disappointing sales figures from major companies in the first half of 2025, including Hutchison China MediTech [1] - Concerns have arisen regarding Trump's phased implementation of drug tariffs, which could escalate to 150% within a year and ultimately reach 250% [1] Group 2: Company Recommendations - The bank's top pick is BeiGene (06160), with a target price set at HKD 230 and a rating of "Outperform," citing strong performance in the first half of 2025 and an improved gross margin guidance despite U.S. tariff impacts [1] - CanSino Biologics (09926) is expected to report adjusted earnings of RMB 23 million for the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, also rated "Outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "Outperform," reflecting confidence in the company's projected 37% year-on-year revenue growth [1] Group 3: Focus on Innovative Drugs - The bank continues to pay attention to licensing deals for Chinese innovative drugs, with expectations of increased subsidies for high-priced innovative drugs, which may drive sales growth for companies such as Kintor Pharmaceutical (02171), Fosun Pharma (02196), WuXi AppTec (02126), and Kelun-Biotech (06990) [2]

Group 1 - The A-share market has shown strong momentum, rising for four consecutive months with trading volume returning to 2 trillion yuan, indicating heightened investor enthusiasm [1] - The current bull market is supported by a solid economic foundation, with China's GDP growth rate reaching 5.3% in the first half of 2025, surpassing the initial target of around 5% [1] - Technology stocks have significantly outperformed, with the STAR Market index rising 22% year-to-date as of August 11, driven by policy support and technological breakthroughs in emerging industries [1] Group 2 - As of August 5, the margin trading balance in A-shares exceeded 2 trillion yuan, but the overall risk remains manageable compared to the 2015 bull market, where the margin balance accounted for 4.73% of the A-share market's circulating value, while currently it is around 2.3% [2] - The current bull market is characterized by policy-driven growth, improved liquidity, and positive market sentiment, with emerging industries like communication equipment, electronic components, and biotechnology leading the gains [2] - Notable stocks in the top twenty by margin trading balance include Jianghuai Automobile and CATL in the new energy sector, as well as technology stocks like Xinyisheng and Zhongji Xuchuang, highlighting investor interest in technology and new energy industries [2] Group 3 - Market opinions on the sustainability of the current bull market vary, with some analysts suggesting it could resemble an "enhanced version of 2013," while others caution about potential obstacles such as weaker-than-expected PPI and completed valuation adjustments [3] - Attention should be paid to changes in policy, technical indicators, and market dynamics, as signs of market turning points may arise from policy statements, volume stagnation, and decreases in margin trading and new account openings [3] - Overall, the A-share market exhibits strong upward momentum, but the certainty of a long-term bull market remains uncertain, necessitating a rational approach from investors [3]